Fredag 4 April | 16:14:33 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-11 08:00 Kvartalsrapport 2025-Q3
2025-08-26 08:00 Kvartalsrapport 2025-Q2
2025-05-15 N/A X-dag ordinarie utdelning ALZCUR 0.00 SEK
2025-05-14 N/A Årsstämma
2025-05-05 08:00 Kvartalsrapport 2025-Q1
2025-02-27 - Bokslutskommuniké 2024
2024-11-11 - Kvartalsrapport 2024-Q3
2024-08-26 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2024-05-14 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-04-25 - Extra Bolagsstämma 2023
2024-02-27 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2023-05-17 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-29 - Extra Bolagsstämma 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-18 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2021-05-17 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-11-17 - Kvartalsrapport 2020-Q3
2020-08-25 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2020-05-20 - Årsstämma
2020-04-29 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-08-31 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning ALZCUR 0.00 SEK
2019-05-22 - Årsstämma
2019-05-01 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AlzeCure Pharma är ett läkemedelsbolag. Bolaget har sin inriktning mot forskning och utveckling av läkemedel som används för diverse hjärnsjukdomar, med störst fokus mot Alzheimers sjukdom, men även mot smärta. Teknologin och forskningen utgår ifrån egen läkemedelsplattform, där bolaget utvecklar olika symptomlindrande och sjukdomsmodifierande läkemedelskandidater. Huvudkontoret ligger i Huddinge.
2025-02-17 10:35:00

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that its project NeuroRestore ACD856 has received €2.5m from the EU's European Innovation Council.

This funding will support AlzeCure’s planned Phase IIa study of NeuroRestore ACD856 in Alzheimer’s patients. In addition, higher doses of ACD856 will be evaluated in humans, as the good safety profile allows for further dosing. ACD856 has the potential to be the first drug in a new category of Alzheimer’s drugs – positive allosteric modulators of Trk receptors (Trk-PAMs), which increase BDNF and NGF signaling.

”We are delighted to have been awarded a €2.5m grant from the European Innovation Council (EIC) for our innovative Alzheimer's treatment. The support from the EIC Accelerator program is a recognition of the project and will be crucial in advancing our clinical trials and bringing this much-needed Alzheimer's treatment to patients,” said Johan Sandin, Chief Scientific Officer at AlzeCure Pharma

ACD856 is a first-in-class drug candidate for Alzheimer's disease with possible positive effects on both memory function and the course of the disease. Phase I clinical studies have shown good safety and tolerability with the substance and that it enters the brain to a high extent and activates regions of the brain with relevance for both cognition and depression. Previous preclinical studies have also shown that AlzeCure's drug candidate ACD856 in the NeuroRestore platform strengthens communication between nerve cells and improves cognitive ability, including learning and memory functions. Furthermore, preclinical results also show neuroprotective, anti-inflammatory and disease-modifying effects in various models with these so-called Trk-PAM substances, which increase BDNF and NGF signaling in the brain.

"The grant we received from the European Innovation Council is a strong validation of NeuroRestore ACD856, which has a unique pharmacological mechanism that enables multiple indications, both neurodegenerative diseases such as Alzheimer's and Parkinson's disease, but also, for example, depression,” said Martin Jönsson, CEO of AlzeCure Pharma. ”That ACD856 has the potential to both improve learning and memory capacity, as well as being disease-modifying and improving brain health is unique and significant”.

Link to the EIC Accelerator announcement: https://eic.ec.europa.eu/news/eic-accelerator-71-companies-selected-most-competitive-funding-round-so-far-2025-02-17_en